- Aktuelle Seite:
-
Home
-
Substanzen
-
Cannabis
- Cannabis als Rauschmittel
Schweiz. Synthesebericht «Cannabis» der Eidgenössischen Kommission für Suchtfragen
Eidgenössische Kommission für Suchtfragen (EKSF), 02.05.2019
Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation
Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow, Steven R. Laviolette
Journal of Neuroscience 30 September 2019, 0708-19; DOI: 10.1523/JNEUROSCI.0708-19.2019
Abstract
https://www.jneurosci.org/content/early/2019/09/27/JNEUROSCI.0708-19.2019
Kanada. Canadian Cannabis Research Database
The Canadian Cannabis Research Database is an online tool that allows individuals to search current and ongoing cannabis research activities underway in Canada. Research since 2015 is covered under 40 possible topics.
The database is intended for researchers, healthcare providers and individuals involved in public health policy. It enables them to search research projects related to the health and social impacts of cannabis, while also fostering communication and collaboration between researchers and identifying potential gaps in cannabis research. (Canadian Centre on Substance Use and Addiction, Kanada)
https://www.ccsa.ca/database-cannabis
Journal of Cannabis Research
Journal of Cannabis Research is an open access, peer-reviewed, international journal which welcomes submissions covering all topics pertaining to cannabis.
The journal is an official publication of the Institute of Cannabis Research at Colorado State University-Pueblo.
https://jcannabisresearch.biomedcentral.com/
Cannabis - A field in flux.
Fifty years ago, cannabis was known as the drug most emblematic of counterculture. Today, many people promote it as a fount of treatments for almost any ailment imaginable. This immense about-turn is reflected in changes in legal regimes: medicinal use of cannabis is now permitted in many countries, and some also allow the drug to be used recreationally. The times, they have a-changed. (Nature Outlook, 28.08.2019)
https://www.nature.com/articles/d41586-019-02523-6
Nabiximols kann Cannabiskonsum vermindern
Sydney – Eine Substitution mit Nabiximols, einer Mischung aus Tetrahydrocannabinol (THC) und Cannabidiol (CBD), hat in einer randomisierten Placebo-kontrollierten Studie in JAMA Internal Medicinedie Psychotherapie der Cannabis-Abhängigkeit unterstützt (2019; doi: 10.1001/jamainternmed.2019.1993). (aerzteblatt.de, 17.09.2019)
https://www.aerzteblatt.de/nachrichten/104706/Nabiximols-kann-Cannabiskonsum-vermindern
EMCDDA. New EMCDDA report highlights greater diversity of cannabis products, increasing potency and the need for close monitoring of health effects
Cannabis products have become increasingly diverse in Europe and close monitoring of their potency and potential health effects is essential. These are among the conclusions of a new report published today by the EU drugs agency (EMCDDA) ahead of International day against drug abuse and illicit trafficking (26 June) (1). The report — Developments in the European cannabis market (2) — provides an overview of emerging and established cannabis products in Europe. (EMCDDA, Lissabon 25.06.2019 (News release No 5/2019))
http://www.emcdda.europa.eu/news/2019/5/developments-in-the-european-cannabis-market_en
The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs.
Ren M, Tang Z, Wu X, Spengler R, Jiang H, Yang Y, Boivin N.
Sci Adv. 2019 Jun 12;5(6):eaaw1391. doi: 10.1126/sciadv.aaw1391. eCollection 2019 Jun.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561734/
Gen des Nikotinrezeptors schützt vor Cannabisabhängigkeit
Aarhus – Menschen mit einer Genvariante im Nikotinrezeptor sind weniger anfällig für eine Cannabis-Abhängigkeit. Dies kam in einer genomweiten Assoziationsstudie in Nature Neuroscience heraus (2019; doi: 10.1038/s41593-019-0416-1). (aerzteblatt.de,20.06.2019)
Chinese tombs yield earliest evidence of cannabis use
Researchers have uncovered the earliest known evidence of cannabis use, from tombs in western China.
The study suggests cannabis was being smoked at least 2,500 years ago, and that it may have been associated with ritual or religious activities. (BBC, 13.06.2019)
https://www.bbc.com/news/science-environment-48624784
Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity.
Wall, M. B., Pope, R., Freeman, T. P., Kowalczyk, O. S., Demetriou, L., Mokrysz, C., … Curran, H. V. (2019).
Journal of Psychopharmacology. doi.org/10.1177/0269881119841568
Abstract
https://journals.sagepub.com/doi/10.1177/0269881119841568
GDS2019: Cannabis health information labels: why it’s time to have mandatory warnings as part of any legal cannabis market and how they’ll help keep the cannabis industry on the straight and narrow.
Professor Adam R Winstock Consultant Psychiatrist & Founder, Global Drug Survey, Mai 2019
Quantifying hepatic enzyme kinetics of (-)-Δ9-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling
Gabriela I. Patilea-Vrana and Jashvant D. Unadkat
Drug Metabolism and Disposition May 2, 2019, dmd.119.086470; doi.org/10.1124/dmd.119.086470
http://dmd.aspetjournals.org/content/dmd/early/2019/05/02/dmd.119.086470.full.pdf
Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.
Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, Shah N, Wu L, Haq K, Solanki S, Kim D, Ahmed A.
Eur J Gastroenterol Hepatol. 2019 Feb;31(2):149-156. doi: 10.1097/MEG.0000000000001263.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467701/
The relationship between motivations for cannabis consumption and problematic use.
Casajuana Kögel C, López-Pelayo H, Oliveras C, Colom J, Gual A, Balcells-Oliveró MM.
Adicciones. 2019 Apr 8;0(0):1221. doi: 10.20882/adicciones.1221. [Epub ahead of print] English, Spanish.
http://adicciones.es/index.php/adicciones/article/view/1221
CBD reduces impairment caused by cannabis
The more cannabidiol (CBD) in a strain of cannabis, the lower the impairment to brain function, according to a new UCL-led brain imaging study. (UCL – University College London, 25.04.2019)
https://www.ucl.ac.uk/news/2019/apr/cbd-reduces-impairment-caused-cannabis
Cannabis Use Disorder.
Patel J, Marwaha R.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 11. PMID: 30844158
https://www.ncbi.nlm.nih.gov/books/NBK538131/
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
Solowij N, Broyd S,Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30661105 Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2.
https://www.ncbi.nlm.nih.gov/pubmed/30661105
CBD kann die Wirkung von THC verstärken
Bislang nahm man an, dass der Cannabisbestandteil Cannabidiol (CBD) keine psychoaktive Wirkung hat und den Effekt des Wirkstoffs THC abmildert. Einer experimentellen Studie zufolge müssen beide Annahmen korrigiert werden. (drugcom.de, 06.03.2019)
https://www.drugcom.de/?id=aktuelles&idx=1210
Cannabisrauchen in Maßen könnte sich auf Spermien auswirken
Boston – Ein geringer Cannabiskonsum könnte sowohl eine höhere Spermienzahl zufolge haben als auch höhere Testosteronwerte. Das ergab eine Beobachtungsstudie mit fast 700 Männern, die in Human Reproduction veröffentlicht wurde (2019; doi: 10.1093/humrep/dez002). Einen kausalen Zusammenhang konnten die Studienautoren allerdings nicht nachweisen. (aerzteblatt.de, 07.02.2019)
Pharmacotherapies for cannabis dependence.
Nielsen S, Gowing L, Sabioni P, Le Foll B.
Cochrane Database Syst Rev. 2019 Jan 28;1:CD008940. doi: 10.1002/14651858.CD008940.pub3.
Abstract
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008940.pub3/full
New trends in cannabis potency in USA and Europe during the last decade (2008-2017).
Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA.
Eur Arch Psychiatry Clin Neurosci. 2019 Jan 22. doi: 10.1007/s00406-019-00983-5.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30671616
Observations: Is Cannabis Good or Bad for Mental Health? The evidence says it can go either way.
(...) The reality is that cannabis cannot be pigeonholed as strictly helpful or harmful. Instead, meaningful discussion about its potential benefits and harms requires careful and nuanced consideration of the scientific literature, coupled with a humble attitude. As delineated in a recent and thorough review paper in the International Review of Psychiatry,the relationship between cannabis and mental health is especially complicated. (Scientific American, 17.01.2019)
https://blogs.scientificamerican.com/observations/is-cannabis-good-or-bad-for-mental-health/
Studie Cannabis-Produkte werden immer stärker
Der THC-Gehalt von Haschisch und Marihuana hat in den letzten Jahren drastisch zugenommen - bei gleichbleibendem Preis. Das birgt erhebliche gesundheitliche Risiken. (Spiegel online, 30.12.2018)
Increasing potency and price of cannabis in Europe, 2006-2016
Tom P. Freeman, Teodora Groshkova, Andrew Cunningham, Roumen Sedefov, Paul Griffiths, Michael T. Lynksey
Addiction, First published: 29 December 2018, doi.org/10.1111/add.14525
https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14525
WHO: Die Übersicht zu Cannabis bleibt unter Verschluss
Die mit Spannung für den 7. Dezember erwartete Veröffentlichung der Ergebnisse der zweijährigen wissenschaftlichen Bewertung von Cannabis, das „Critical Review on Cannabis“, im Rahmen des CND-Treffens (Commission on Narcotic Drugs) in Wien, fand nicht statt. Die letzte Einschätzung der WHO aus dem Jahr 1954 hatte das weltweite Verbot im Rahmen des UNO-Drogenkontrollvertrags gestärkt.
Als es an der Zeit war, die Ergebnisse im überfüllten Saal zugänglich zu machen, waren alle verblüfft, zu erleben, wie der Sprecher der WHO bekannt gab, dass das Ergebnis zu Cannabis vertraulich bleibt, und nicht einmal einen weiteren Termin für die Veröffentlichung nannte. Sprecher von Nicht-Regierungs-Organisationen kritisierten, dass die WHO sich nicht an ihre eigenen Regeln und Richtlinien halte. (IACM, 22.12.2018)
http://www.cannabis-med.org/german/bulletin/ww_de_db_cannabis_artikel.php?id=553#1
WHO. „...the outcome on Cannabis was kept confidential“
Vienna, UN headquarters. World Health Organization (WHO) much anticipated release of findings of two year scientific assessment of Cannabis leaves observers stunned and upset.The last assessment by WHO in 1954 fuelled global prohibition under the UN drug control Treaty framework. (FAAAT think & do tank, 07.12.2018)
http://conference.faaat.net/blog/press-statement-faaat-think-do-tank
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial
D'Souza, Deepak Cyril et al.
The Lancet Psychiatry , Volume 0 , Issue 0 , online first, Published:December 06, 2018, doi.org/10.1016/S2215-0366(18)30427-9
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30427-9/fulltext
Cannabis Systematics at the Levels of Family, Genus, and Species.
McPartland JM.
Cannabis Cannabinoid Res. 2018 Oct 1;3(1):203-212. doi: 10.1089/can.2018.0039.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225593/
The Crimson Digest (Volume 1): Briefing on the international scientific assessment of cannabis: Processes, stakeholders and history
FAAAT, 2018
http://faaat.net/wp-content/uploads/CRIMSONDIGESTvol1_web.pdf
Seite 1 von 5